CN116456968B - 生长抑素调节剂的制剂 - Google Patents

生长抑素调节剂的制剂

Info

Publication number
CN116456968B
CN116456968B CN202180068588.2A CN202180068588A CN116456968B CN 116456968 B CN116456968 B CN 116456968B CN 202180068588 A CN202180068588 A CN 202180068588A CN 116456968 B CN116456968 B CN 116456968B
Authority
CN
China
Prior art keywords
weight
spray
compound
tablet
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180068588.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN116456968A (zh
Inventor
杰拉尔德·伯克
伊恩·叶提斯
汉纳·布洛夫斯基
凯尔·基伯兹
克莱顿·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crinetics Pharmaceuticals Inc
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Priority to CN202610102122.4A priority Critical patent/CN121943816A/zh
Publication of CN116456968A publication Critical patent/CN116456968A/zh
Application granted granted Critical
Publication of CN116456968B publication Critical patent/CN116456968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180068588.2A 2020-09-09 2021-09-07 生长抑素调节剂的制剂 Active CN116456968B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610102122.4A CN121943816A (zh) 2020-09-09 2021-09-07 生长抑素调节剂的制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076024P 2020-09-09 2020-09-09
US63/076,024 2020-09-09
PCT/US2021/049282 WO2022055880A1 (en) 2020-09-09 2021-09-07 Formulations of a somatostatin modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610102122.4A Division CN121943816A (zh) 2020-09-09 2021-09-07 生长抑素调节剂的制剂

Publications (2)

Publication Number Publication Date
CN116456968A CN116456968A (zh) 2023-07-18
CN116456968B true CN116456968B (zh) 2026-03-20

Family

ID=78078387

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180068588.2A Active CN116456968B (zh) 2020-09-09 2021-09-07 生长抑素调节剂的制剂
CN202610102122.4A Pending CN121943816A (zh) 2020-09-09 2021-09-07 生长抑素调节剂的制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610102122.4A Pending CN121943816A (zh) 2020-09-09 2021-09-07 生长抑素调节剂的制剂

Country Status (27)

Country Link
US (3) US11266641B1 (https=)
EP (2) EP4210700B1 (https=)
JP (2) JP7796115B2 (https=)
KR (1) KR20230066379A (https=)
CN (2) CN116456968B (https=)
AR (1) AR123453A1 (https=)
AU (1) AU2021341936A1 (https=)
CA (1) CA3191084A1 (https=)
CL (1) CL2023000627A1 (https=)
CO (1) CO2023004346A2 (https=)
DK (1) DK4210700T3 (https=)
ES (1) ES3040117T3 (https=)
FI (1) FI4210700T3 (https=)
HR (1) HRP20250995T1 (https=)
IL (1) IL301038A (https=)
LT (1) LT4210700T (https=)
MA (1) MA66139B1 (https=)
MD (1) MD4210700T2 (https=)
MX (1) MX2023002761A (https=)
PE (1) PE20231850A1 (https=)
PL (1) PL4210700T3 (https=)
PT (1) PT4210700T (https=)
RS (1) RS67208B1 (https=)
SI (1) SI4210700T1 (https=)
SM (1) SMT202500315T1 (https=)
WO (1) WO2022055880A1 (https=)
ZA (1) ZA202303250B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264178B2 (en) 2016-07-14 2024-05-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
CA3191084A1 (en) 2020-09-09 2022-03-17 Gerald Burke Formulations of a somatostatin modulator
WO2023137018A1 (en) * 2022-01-11 2023-07-20 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of carcinoid syndrome
PE20260136A1 (es) * 2022-05-11 2026-01-21 Lilly Co Eli Composiciones farmaceuticas de glp1
CN115919866A (zh) * 2022-12-07 2023-04-07 深圳海王医药科技研究院有限公司 特泊替尼固体分散体及其制备方法
KR20250162795A (ko) 2023-03-28 2025-11-19 크리네틱스 파마슈티칼스, 인크. 간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법
JP7797570B2 (ja) 2023-05-23 2026-01-13 ユルチョン・ケミカル・カンパニー・リミテッド セルパウチ用フィルム及びその保管方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021011641A1 (en) * 2019-07-17 2021-01-21 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
CN117377473A (zh) * 2021-05-25 2024-01-09 克林提克斯医药股份有限公司 生长抑素调节剂用于治疗疾病的用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
WO2003066055A1 (en) 2002-02-04 2003-08-14 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
US7767817B2 (en) 2003-09-05 2010-08-03 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007098214A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
AU2007309708A1 (en) 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
HRP20180328T1 (hr) * 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP5564045B2 (ja) 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
RU2013113627A (ru) * 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
RU2637936C2 (ru) 2011-05-23 2017-12-08 Элан Фармасьютикалз, Инк. Ингибиторы активности киназы lrrk2
WO2012163354A1 (en) 2011-05-31 2012-12-06 Linak A/S Actuator
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
KR20150039832A (ko) 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
US9643951B2 (en) 2013-09-30 2017-05-09 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JPWO2015146929A1 (ja) 2014-03-24 2017-04-13 武田薬品工業株式会社 複素環化合物
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
MX2019000246A (es) 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
IL264178B2 (en) 2016-07-14 2024-05-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
EP3596062A4 (en) 2017-03-16 2020-08-26 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND THEIR USES
WO2018208987A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
CN110913840A (zh) 2017-08-11 2020-03-24 默克专利股份公司 包含3-氟-4-[7-甲氧基-3-甲基-8-(1-甲基-1H-吡唑-4-基)-2-氧代-2,3-二氢-咪唑并[4,5-c]喹啉-1-基]-苄腈的药物制剂
PT3740475T (pt) 2018-01-17 2022-07-18 Crinetics Pharmaceuticals Inc Processo de produção de moduladores da somatostatina
SMT202500155T1 (it) 2018-09-18 2025-05-12 Crinetics Pharmaceuticals Inc Modulatori della somatostatina e loro usi
CA3191084A1 (en) 2020-09-09 2022-03-17 Gerald Burke Formulations of a somatostatin modulator
BR112023024465A2 (pt) 2021-05-25 2024-02-06 Crinetics Pharmaceuticals Inc Usos de um modulador de somatostatina para o tratamento de doença

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021011641A1 (en) * 2019-07-17 2021-01-21 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
CN117377473A (zh) * 2021-05-25 2024-01-09 克林提克斯医药股份有限公司 生长抑素调节剂用于治疗疾病的用途

Also Published As

Publication number Publication date
US20240398782A1 (en) 2024-12-05
AU2021341936A9 (en) 2025-03-20
AU2021341936A1 (en) 2023-05-25
HRP20250995T1 (hr) 2025-12-05
US11957674B2 (en) 2024-04-16
JP2026067866A (ja) 2026-04-21
US20220071986A1 (en) 2022-03-10
KR20230066379A (ko) 2023-05-15
CL2023000627A1 (es) 2023-09-01
SMT202500315T1 (it) 2025-11-10
FI4210700T3 (fi) 2025-09-16
MD4210700T2 (ro) 2025-11-30
MA66139B1 (fr) 2025-09-30
DK4210700T3 (da) 2025-09-08
ES3040117T3 (en) 2025-10-28
ZA202303250B (en) 2025-08-27
CN121943816A (zh) 2026-05-01
CA3191084A1 (en) 2022-03-17
US20220143007A1 (en) 2022-05-12
JP2023540137A (ja) 2023-09-21
IL301038A (en) 2023-05-01
PL4210700T3 (pl) 2025-10-20
JP7796115B2 (ja) 2026-01-08
EP4635497A3 (en) 2025-11-19
WO2022055880A1 (en) 2022-03-17
RS67208B1 (sr) 2025-10-31
US11266641B1 (en) 2022-03-08
TW202227072A (zh) 2022-07-16
MX2023002761A (es) 2023-04-03
EP4210700B1 (en) 2025-08-06
EP4210700A1 (en) 2023-07-19
EP4635497A2 (en) 2025-10-22
AR123453A1 (es) 2022-11-30
PT4210700T (pt) 2025-09-01
LT4210700T (lt) 2025-10-10
PE20231850A1 (es) 2023-11-21
CN116456968A (zh) 2023-07-18
SI4210700T1 (sl) 2025-12-31
CO2023004346A2 (es) 2023-04-27

Similar Documents

Publication Publication Date Title
CN116456968B (zh) 生长抑素调节剂的制剂
JP6530845B2 (ja) イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法
US20240366587A1 (en) Uses of a somatostatin modulator for the treatment of disease
JP7378279B2 (ja) ニロチニブを有効成分とする医薬錠剤及びその製造方法
US20250228842A1 (en) Uses of a somatostatin modulator for the treatment of carcinoid syndrome
CN117377473A (zh) 生长抑素调节剂用于治疗疾病的用途
EA049599B1 (ru) Составы модулятора соматостатина
HK40093963A (en) Formulations of a somatostatin modulator
HK40093963B (en) Formulations of a somatostatin modulator
JP4572296B2 (ja) ピモベンダン経口投与製剤
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
JP2017071560A (ja) イルベサルタンを含有する医薬組成物及びその製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant